Collaborative and Other Relationships (Tables)

12 Months Ended

Dec. 31, 2012

Organization, Consolidation and Presentation of Financial Statements [Abstract]



			Before First New Product FDA Approval
Co-promotion Operating Profits†	After First New Product FDA Approval		First Non-CLL GA101 FDA Approval Occurs First		GA101 CLL Sales Trigger Occurs First
I. First $50.0 million	30	%	30	%	30	%
II. Above $50.0 million	—	%	—	%	35	%
A. Until First GA101 Threshold Date	38	%	39	%	—	%
B. After First GA101 Threshold Date
1(a). Until First Threshold Date	37.5	%	—	%	—	%
1(b). After First Threshold Date and until Second Threshold Date	35	%	—	%	—	%
1(c). After Second Threshold Date	30	%	—	%	—	%
2. Until Second GA101 Threshold Date	—	%	37.5	%	—	%
C. After Second GA101 Threshold Date	—	%	35	%	—	%

†

First GA101 Threshold Date means the earlier of (1) the date of the First Non-CLL GA101 FDA Approval if U.S. gross sales of GA101 for the preceding consecutive 12 month period were at least $150.0 million or (2) the first day of the calendar quarter after the date of the First Non-CLL GA101 FDA Approval that U.S. gross sales of GA101 within any consecutive 12 month period have reached $150.0 million.

Second GA101 Threshold Date means the first day of the calendar quarter after U.S. gross sales of GA101 within any consecutive 12 month period have reached $500.0 million.

First Threshold Date means the earlier of (1) the GA101 CLL Sales Trigger, (2) the Second GA101 Threshold Date and (3) the later of (a) the first date that U.S. gross sales of New Products in any calendar year reach $150.0 million and (b) January 1 of the calendar year following the calendar year in which the First New Product FDA Approval occurs if gross sales of New Products reached $150.0 million within the same calendar year in which the First New Product FDA Approval occurred.

Second Threshold Date means the later of (1) the first date that U.S. gross sales of New Products in any calendar year reach $350.0 million and (2) January 1 of the calendar year following the calendar year in which the First Threshold Date occurs.

Revenues from unconsolidated joint business



	For the Years Ended December 31,
(In millions)	2012		2011		2010
Biogen Idec’s share of pre-tax co-promotion profits in the U.S.	$	1,031.7	$	872.7	$	848.0
Reimbursement of selling and development expenses in the U.S.	1.6		6.1		58.3
Revenue on sales of RITUXAN in the rest of world	104.6		117.8		170.9
Total unconsolidated joint business revenues	$	1,137.9	$	996.6	$	1,077.2

Summary of activity related to collaboration with Acorda



	For the Years Ended December 31,
(In millions)	2012		2011		2010
Upfront and milestones payments made to Acorda	$	—	$	25.0	$	—
Total development expense incurred by Biogen Idec Inc. excluding upfront and milestones payments	$	18.6	$	22.3	$	22.8
Total commercialization expense incurred by Biogen Idec	$	51.2	$	14.7	$	—
Total expense reflected within our statements of income	$	69.8	$	37.0	$	22.8
Total capitalized as an intangible asset	$	—	$	25.0	$	—

Summary of activity related to collaboration, along with an estimate of additional future development expense



(In millions)	As of December 31, 2012
Total upfront and milestone payments made to Acorda	$	135.0
Total expense incurred by Biogen Idec, excluding upfront and milestone payments	$	134.3

Mechanism for reimbursement, under the amended agreement amounts payable



			Rates should Sobi exercise its option right⁽³⁾
Royalty and Net Revenue Share Rates:	Method	Rate prior to 1st commercial sale in the Sobi Territory:	Base Rate following 1st commercial sale in the Sobi Territory:	Rate during the Reimbursement Period:
Sobi rate to Biogen on net sales in the Sobi Territory	Royalty	N/A	10 to 12%	Base Rate plus 5%
Biogen rate to Sobi on net sales in the Biogen North America Territory	Royalty	2%	10 to 12%	Base Rate less 5%
Biogen rate to Sobi on net sales in the Biogen Direct Territory	Royalty	2%	15 to 17%	Base Rate less 5%
Biogen rate to Sobi on net revenue⁽¹⁾ from the Biogen Distributor Territory⁽²⁾	Net Revenue Share	10%	50%	Base Rate less 15%


(1)	Net revenue represents Biogen Idec’s pre-tax receipts from third-party distributors, less expenses incurred by Biogen Idec in the conduct of commercialization activities supporting the distributor activities.


(2)	The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.


(3)	A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen Idec to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.

Summary of activity related to collaboration with Swedish Orphan Biovitrum



	For the Years Ended December 31,
(In millions)	2012		2011		2010
Total development expense incurred by Biogen Idec Inc.	$	142.9	$	129.6	$	78.9
Total expense incurred by Biogen Idec Inc. associated with commercial capabilities in preparation for the potential product launch	$	44.7	$	18.6	$	—
Total expense reflected within our consolidated statements of income	$	187.6	$	148.2	$	78.5

Summary of activity related to collaboration, along with an estimate of additional future development expense



(In millions)	As of December 31, 2012
Total upfront and milestone payments received from Sobi	$	5.0
Total expense incurred by Biogen Idec Inc., excluding upfront and milestone payments	$	468.9
Estimate of additional amounts expected to be incurred by Biogen Idec in development of Factors VIII and IX	$	373.0

Summary of activity related to collaboration with AbbVie Inc.



	For the Years Ended December 31,
(In millions)	2012		2011		2010
Total development expense incurred by the collaboration	$	128.0	$	105.2	$	74.8
Biogen Idec’s share of expense reflected within our consolidated statements of income	$	65.6	$	54.2	$	37.4

Summary of activity related to collaboration, along with an estimate of additional future development expense



(In millions)	As of December 31, 2012
Total upfront and milestone payments made to AbbVie	$	80.0
Total expense incurred by Biogen Idec, excluding upfront and milestone payments	$	279.7
Estimate of additional amounts to be incurred by us in development of current indications of daclizumab	$	222.1

Summary of activity related to collaboration with Portola Pharmaceuticals, Inc.



	For the Years Ended December 31,
(In millions)	2012		2011		2010
Total expense incurred by the collaboration	$	18.8	$	1.1	$	—
Total expense reflected within our consolidated statements of income, excluding upfront and milestone payments	$	14.2	$	0.9	$	—

Summary of activity related to collaboration, along with an estimate of additional future development expense



(In millions)	As of December 31, 2012
Total upfront payments paid to Portola	$	36.8
Total development expense incurred by Biogen Idec Inc., excluding upfront and milestone payments	$	15.1
Estimate of additional amounts to be incurred by Biogen Idec in development of current indications of Syk inhibitor	$	695.1

Summary of activity related to collaboration with Isis Pharmaceuticals



	For the Years Ended December 31,
(In millions)	2012		2011		2010
Total expense incurred by Biogen Idec Inc.	$	0.6	$	—	$	—
Total expense reflected within our consolidated statements of income, excluding upfront and milestone payments	$	0.6	$	—	$	—

Summary of activity related to collaboration, along with an estimate of additional future development expense



(In millions)	As of December 31, 2012
Total upfront payments paid to Isis	$	71.0
Total development expense incurred by Biogen Idec Inc., excluding upfront and milestone payments	$	0.6
Estimate of additional amounts to be incurred by Biogen Idec in development of DM1 and SMA	$	697.6